CWA
FOLD

Clarus Wealth Advisors’s Amicus Therapeutics FOLD Stock Holding History

Clarus Wealth Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,278
Closed -$16K – 287
2019
Q2 		$16K Hold
1,278
– – 0.01% 392
2019
Q1 		$17K Hold
1,278
– – 0.01% 444
2018
Q4 		$12K Buy
1,278
+639
+100% +$7.02K 0.02% 475
2018
Q3 		$8K Buy
+639
New +$8.94K 0.01% 566

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Clarus Wealth Advisors's FOLD Position: Q3 2019 in Review

Clarus Wealth Advisors sold out of Amicus Therapeutics (FOLD) in Q3 2019, closing a stake of 1,278 shares — an estimated $16K sold.

Clarus Wealth Advisors first reported a position in FOLD in Q3 2018 and held it in 4 quarters. The position peaked at $17K in Q1 2019. 205 funds tracked by Wall St. Rank hold FOLD as of Q3 2019.

  • Clarus Wealth Advisors reported no remaining Amicus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Clarus Wealth Advisors sold 1,278 Amicus Therapeutics shares in Q3 2019, an estimated $16K.
  • Clarus Wealth Advisors first reported a position in Amicus Therapeutics in Q3 2018 and held it in 4 quarters.
  • Clarus Wealth Advisors's Amicus Therapeutics position peaked at $17K in Q1 2019.
  • 205 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2019.

Based on Clarus Wealth Advisors's 13F filing for Q3 2019, filed 11 Oct 2019.